Logo image of INSM

INSMED INC (INSM) Stock Fundamental Analysis

NASDAQ:INSM - Nasdaq - US4576693075 - Common Stock - Currency: USD

76.29  -5.26 (-6.45%)

After market: 76.29 0 (0%)

Fundamental Rating

3

Overall INSM gets a fundamental rating of 3 out of 10. We evaluated INSM against 571 industry peers in the Biotechnology industry. INSM may be in some trouble as it scores bad on both profitability and health. INSM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

INSM had negative earnings in the past year.
INSM had a negative operating cash flow in the past year.
INSM had negative earnings in each of the past 5 years.
INSM had a negative operating cash flow in each of the past 5 years.
INSM Yearly Net Income VS EBIT VS OCF VS FCFINSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

INSM has a Return On Assets of -45.12%. This is comparable to the rest of the industry: INSM outperforms 50.36% of its industry peers.
INSM has a worse Return On Equity (-320.20%) than 76.43% of its industry peers.
Industry RankSector Rank
ROA -45.12%
ROE -320.2%
ROIC N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INSM Yearly ROA, ROE, ROICINSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

Looking at the Gross Margin, with a value of 76.43%, INSM belongs to the top of the industry, outperforming 85.18% of the companies in the same industry.
INSM's Gross Margin has been stable in the last couple of years.
INSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
INSM Yearly Profit, Operating, Gross MarginsINSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INSM has more shares outstanding
The number of shares outstanding for INSM has been increased compared to 5 years ago.
The debt/assets ratio for INSM has been reduced compared to a year ago.
INSM Yearly Shares OutstandingINSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
INSM Yearly Total Debt VS Total AssetsINSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of 1.70, we must say that INSM is in the distress zone and has some risk of bankruptcy.
INSM has a better Altman-Z score (1.70) than 71.43% of its industry peers.
A Debt/Equity ratio of 3.95 is on the high side and indicates that INSM has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.95, INSM is doing worse than 84.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.95
Debt/FCF N/A
Altman-Z 1.7
ROIC/WACCN/A
WACC9.12%
INSM Yearly LT Debt VS Equity VS FCFINSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

INSM has a Current Ratio of 5.45. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
INSM's Current ratio of 5.45 is in line compared to the rest of the industry. INSM outperforms 58.21% of its industry peers.
A Quick Ratio of 5.12 indicates that INSM has no problem at all paying its short term obligations.
The Quick ratio of INSM (5.12) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.45
Quick Ratio 5.12
INSM Yearly Current Assets VS Current LiabilitesINSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The earnings per share for INSM have decreased by -4.59% in the last year.
The Revenue has grown by 19.17% in the past year. This is quite good.
INSM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.65% yearly.
EPS 1Y (TTM)-4.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.73%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%24.79%

3.2 Future

INSM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.44% yearly.
INSM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 65.72% yearly.
EPS Next Y16.18%
EPS Next 2Y22.68%
EPS Next 3Y27.56%
EPS Next 5Y25.44%
Revenue Next Year37.17%
Revenue Next 2Y68.44%
Revenue Next 3Y80.58%
Revenue Next 5Y65.72%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INSM Yearly Revenue VS EstimatesINSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
INSM Yearly EPS VS EstimatesINSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INSM. In the last year negative earnings were reported.
Also next year INSM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INSM Price Earnings VS Forward Price EarningsINSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INSM Per share dataINSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

INSM's earnings are expected to grow with 27.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.68%
EPS Next 3Y27.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INSM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INSMED INC

NASDAQ:INSM (3/3/2025, 6:23:57 PM)

After market: 76.29 0 (0%)

76.29

-5.26 (-6.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/bmo
Earnings (Next)05-07 2025-05-07
Inst Owners112.91%
Inst Owner Change1.62%
Ins Owners1.06%
Ins Owner Change3.57%
Market Cap13.65B
Analysts85.22
Price Target92.77 (21.6%)
Short Float %8.23%
Short Ratio7.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.57%
Min EPS beat(2)-10.77%
Max EPS beat(2)-2.38%
EPS beat(4)1
Avg EPS beat(4)-11.94%
Min EPS beat(4)-50.18%
Max EPS beat(4)15.57%
EPS beat(8)2
Avg EPS beat(8)-13.85%
EPS beat(12)4
Avg EPS beat(12)-10.19%
EPS beat(16)5
Avg EPS beat(16)-8.17%
Revenue beat(2)0
Avg Revenue beat(2)-0.97%
Min Revenue beat(2)-1.53%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-1.51%
Min Revenue beat(4)-4.81%
Max Revenue beat(4)0.7%
Revenue beat(8)2
Avg Revenue beat(8)-0.25%
Revenue beat(12)3
Avg Revenue beat(12)-0.28%
Revenue beat(16)5
Avg Revenue beat(16)-0.34%
PT rev (1m)3.19%
PT rev (3m)2.34%
EPS NQ rev (1m)-2.19%
EPS NQ rev (3m)-5.83%
EPS NY rev (1m)-3.74%
EPS NY rev (3m)-6.25%
Revenue NQ rev (1m)2.37%
Revenue NQ rev (3m)4.15%
Revenue NY rev (1m)-3.34%
Revenue NY rev (3m)-1.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.53
P/FCF N/A
P/OCF N/A
P/B 47.83
P/tB 150.62
EV/EBITDA N/A
EPS(TTM)-5.58
EYN/A
EPS(NY)-4.68
Fwd EYN/A
FCF(TTM)-3.95
FCFYN/A
OCF(TTM)-3.82
OCFYN/A
SpS2.03
BVpS1.6
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.12%
ROE -320.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.43%
FCFM N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 3.95
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 159.73%
Cap/Sales 6.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.45
Quick Ratio 5.12
Altman-Z 1.7
F-Score4
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)113.37%
Cap/Depr(5y)86.53%
Cap/Sales(3y)4.8%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.73%
EPS Next Y16.18%
EPS Next 2Y22.68%
EPS Next 3Y27.56%
EPS Next 5Y25.44%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%24.79%
Revenue Next Year37.17%
Revenue Next 2Y68.44%
Revenue Next 3Y80.58%
Revenue Next 5Y65.72%
EBIT growth 1Y-15.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.95%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.53%
OCF growth 3YN/A
OCF growth 5YN/A